LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer is a research paper published in Communications Biology (2021). On theSindex it has a DataRank of 0. It has been cited 23 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: F31 CA257298
BLRD VA
Grant: I01 BX004545
NIH HHS
Grant: S10 OD021805
NCATS NIH HHS
Grant: UL1 TR002645
NCI NIH HHS
Grant: P30 CA054174
NCI NIH HHS
Grant: R01 CA239227
NCI NIH HHS
Grant: R01 CA179120
National Institutes of Health
Grant: 1UL1TR002645-01
Institute for Integration of Medicine & Science: A Partnership to Improve Health
National Institutes of Health
Grant: 5I01BX004545-04
Development of Potent Inhibitors of proto-oncogene PELP1 for Treating Advanced Breast Cancer
National Institutes of Health
Grant: 5P30CA054174-16
SAN ANTONIO CANCER INSTITUTE
National Institutes of Health
Grant: 1S10OD021805-01
High Throughput DNA Sequencer: Illumina HiSeq 3000 Sequencer
National Institutes of Health
Grant: 5R01CA179120-03
miRNAs:Safe and effective therapeutic adjuvants for treating drug resistant TNBC
FWCI
1.26
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals